利奈唑胺致血小板减少病例报告1例

doi:10.13438/j.cnki.jdzk.2022.05.015

吉首大学学报（自然科学版） ›› 2022, Vol. 43 ›› Issue (5): 93-96.DOI: 10.13438/j.cnki.jdzk.2022.05.015

• 加工应用 • 上一篇

利奈唑胺致血小板减少病例报告1例

龙小康，彭馨，徐幸民，宋奎，郑云飞，陈超，黎敏

（1.湘西土家族苗族自治州人民医院，湖南吉首 416000；2.吉首大学医学院，湖南吉首 416000）

出版日期:2022-09-25 发布日期:2023-01-11
通讯作者: 黎敏（1977—），女，湖南湘潭人，湘西土家族苗族自治州人民医院主任医师，博士，主要从事儿科学研究.
作者简介:龙小康（1992—），男，湖南湘西人，湘西土家族苗族自治州人民医院药师，硕士，主要从事临床药学研究；彭馨（1997—），女，湖南湘西人，吉首大学医学院住院医师，主要从事妇产科研究，为本文共同第一作者
基金资助:
吉首大学校级科研项目（JDZD21002）

A Case Report of Thrombocytopenia Caused by Linezolid

LONG Xiaokang,PENG Xin,XU Xingmin,SONG Kui,ZHENG Yunfei,CHEN Chao,LI Ming

(1.Xiangxi Autonomous Prefecture People's Hospital,Jishou 416000,Hunan China;2.Jishou University School of Medicine,Jishou 416000,Hunan China)

Online:2022-09-25 Published:2023-01-11

摘要/Abstract

摘要：报道了1例利奈唑胺引起血小板减少的病例，介绍了利奈唑胺诱导血小板减少症的发生机制、危险因素及防治措施.根据不良反应关联性评价分析，该患者出现血小板减少很可能与其使用利奈唑胺相关.目前，利奈唑胺诱导血小板减少症的发生机制尚不明确，长疗程用药、肾功能不全、基线时血小板计数低是利奈唑胺诱导血小板减少症的独立危险因素.临床药师应当加强药学监护，提高早期防范意识，避免药物不良反应发生.

关键词： 利奈唑胺, 血小板减少症, 抗感染治疗, 药物不良反应

Abstract: This paper reports a case of linezolid induced thrombocytopenia,and introduces the mechanism,risk factors,prevention and treatment.According to the analysis of adverse reaction correlation evaluation,this case of thrombocytopenia is probably related to the use of linezolid.At present,the mechanism of linezolid induced thrombocytopenia is still unclear.Long-term medication,renal dysfunction,and low platelet count at baseline are independent risk factors.Clinical pharmacists should strengthen pharmaceutical care,improve early prevention awareness,and avoid adverse drug reactions.

Key words: linezolid, thrombocytopenia, antimicrobial therapy, adverse drug reaction

龙小康, 彭馨, 徐幸民, 宋奎, 郑云飞, 陈超, 黎敏. 利奈唑胺致血小板减少病例报告1例[J]. 吉首大学学报（自然科学版）, 2022, 43(5): 93-96.

LONG Xiaokang, PENG Xin, XU Xingmin, SONG Kui, ZHENG Yunfei, CHEN Chao, LI Ming. A Case Report of Thrombocytopenia Caused by Linezolid[J]. Journal of Jishou University(Natural Sciences Edition), 2022, 43(5): 93-96.

参考文献

[1] DRYDEN MATTHEW S.Linezolid Pharmacokinetics and Pharmacodynamics in Clinical Treatment[J].Journal of Antimicrobial Chemotherapy,2011,66 (Suppl 4):iv7-iv15.
[2] POULAKOS MARA N,GRACE YASMIN,COAKLEY CHRISTINA.Probable Linezolid-Induced Thrombocytopenia in a Patient with Vancomycin-Resistant Enterococci[J].Journal of Pharmacy Practice,2012,25(6):615-618.
[3] COSSU A P,MUSU M,MURA P,et al.Linezolid-Induced Thrombocytopenia in Impaired Renal Function:Is it Time for a Dose Adjustment? A Case Report and Review of Literature[J].European Journal of Clinical Pharmacology,2014,70(1):23-28.
[4] 张乃菊,张帆,陈天平,等.1例利奈唑胺致血小板减少症病例的原因分析[J].抗感染药学,2020,17(12):1822-1824.
[5] 张亚楠,丁华.1例利奈唑胺致血小板减少的病例分析[J].北方药学,2021,18(6):179-181.
[6] 魏戌,谢雁鸣.国内外不良反应因果判断原则及评价方法解读[J].中国中药杂志,2012,37(18):2744-2747.
[7] KUTER DAVID J,PHIL M D,TILLOTSON GLENN S,et al.Hematologic Effects of Antimicrobials:Focus on the Oxazolidinone Linezolid[J].Pharmacotherapy:The Journal of Human Pharmacology and Drug Therapy,2001,21(8):1010-1013.
[8] GERSON STANTON L,KAPLAN SHELDON L,BRUSS JON B,et al.Hematologic Effects of Linezolid:Summary of Clinical Experience[J].Antimicrobial Agents and Chemotherapy,2002,46(8):2723-2726.
[9] ORRICK JOANNE J,JOHNS THOMAS,JANELLE JENNIFER,et al.Thrombocytopenia Secondary to Linezolid Administration:What is the Risk? [J].Clinical Infectious Diseases,2002,35(3):348-349.
[10] MINSON QUENTIN,GENTRY CHRIS A.Analysis of Linezolid-Associated Hematologic Toxicities in a Large Veterans Affairs Medical Center[J].Pharmacotherapy:The Journal of Human Pharmacology and Drug Therapy,2010,30(9):895-903.
[11] LIN YEN-HUNG,WU VIN-CENT,TSAI I-JUNG,et al.High Frequency of Linezolid-Associated Thrombocytopenia Among Patients with Renal Insufficiency[J].International Journal of Antimicrobial Agents,2006,28(4):345-351.
[12] 钟玲,邵华,陈燕,等.利奈唑胺诱导血小板减少症的研究进展[J].中国临床药理学与治疗学,2018,23(10):1196-1200.
[13] BALLESTEROS GARCA MARA DEL M,ORS MILIN MARA E,VELZQUEZ ELENA DAZ,et al.Mielosupresión Inducida por Linezolid:Un Caso Pediátrico[J].Arch Argent Pediatr,2017,115(6):e420-e423.
[14] GREEN STEPHEN L,MADDOX JOHN C,HUTTENBACH ERICD.Linezolid and Reversible Myelosuppression[J].Journal of the American Medical Association,2001,285(10):1973-1974.
[15] MONSON THOMAS,SCHICHMAN STEVEN A,ZENT CLIVE S.Linezolid-Induced Pure Red Blood Cell Aplasia[J].Clinical Infectious Diseases,2002,35(3):e29-e31.
[16] LAM SUM.Linezolid-Associated Thrombocytopenia[J].The Consultant Pharmacist,2012,27(7):504-508.
[17] PASCOALINHO DULCE,VILAS MARIA JOO,COELHO LUS,et al.Linezolid-Related Immune-Mediated Severe Thrombocytopenia[J].International Journal of Antimicrobial Agents,2011,37(1):88-89.
[18] RABON ALYSSA D,FISHER JON P,MACVANE SHAWN H.Incidence and Risk Factors for Development of Thrombocytopenia in Patients Treated with Linezolid for 7 Days or Greater[J].Annals of Pharmacotherapy,2018,53(2):220-221.
[19] 窦林杰,韩欣妍,董海燕.利奈唑胺致血小板减少症研究进展[J].中国感染与化疗杂志,2019,19(1):96-100.
[20] 白艳,王羽凝,李其,等.利奈唑胺不良反应的文献计量分析[J].中国临床药理学杂志,2015,31(24):2459-2461.
[21] 陈璋璋,吕迁洲.利奈唑胺相关血小板减少的危险因素分析[J].药物不良反应杂志,2012,(4):6-10.
[22] 黄丽,陆向红,罗佳.33例利奈唑胺致血小板减少的文献分析[J].中国药物警戒,2014,11(5):301-303.
[23] BRIER MICHAEL E,STALKER DENNIS J,ARONOFF GEORGE R,et al.Pharmacokinetics of Linezolid in Subjects with Renal Dysfunction[J].Antimicrobial Agents and Chemotherapy,2003,47(9):2775-2780.
[24] HIRANO RYUICHI,SAKAMOTO YUICHI,TACHIBANA NAOKI,et al.Retrospective Analysis of the Risk Factors for Linezolid-Induced Thrombocytopenia in Adult Japanese Patients[J].International Journal of Clinical Pharmacy,2014,36(4):795-799.

利奈唑胺致血小板减少病例报告1例

A Case Report of Thrombocytopenia Caused by Linezolid

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价